MENS
Jyong Biotech Ltd.
$2.20
▲ +17.02%$2.20▼ -73.14%
over 1Y
L $1.46EODHDH $65.62
Today+17.0%
1W+15.8%
1M+8.9%
3M-10.2%
YTD-35.5%
1Y—
Hold
Conviction
Horizon
Medium (3–12mo)
Conservative balance sheet (liabilities/equity -1.83x).
Liabilities / equity -1.83x · latest
Jyong Biotech Ltd. shows limited reported revenue.
Supporting the case: conservative balance sheet (liabilities/equity -1.83x).
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$2.80M | -$2.06M | -$2.61M |
| Net income | -$4.40M | -$3.02M | -$4.67M |
| Diluted EPS | -$0.06 | -$0.04 | -$0.06 |
| Net margin | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$187M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-2.7%
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt$17.5M
Net cash-$16.3M
Capital returns
Buyback yield9.6%
Dividend yield (est.)—
Shareholder yield9.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Recent filings
all on EDGAR ↗20-FPeriod ending 2025-12-312026-05-15open ↗NT 20-FPeriod ending 2025-12-312026-04-29open ↗SCHEDULE 13DFiling2026-04-24open ↗3Period ending 2026-04-132026-04-14open ↗3Period ending 2026-04-082026-04-08open ↗3Period ending 2026-04-012026-04-01open ↗3Period ending 2026-04-012026-04-01open ↗3Period ending 2026-04-012026-04-01open ↗3Period ending 2026-04-012026-04-01open ↗3Period ending 2026-04-012026-04-01open ↗6-KPeriod ending 2026-02-062026-02-06open ↗6-KPeriod ending 2026-01-092026-01-09open ↗
Frequently asked
- Is Jyong Biotech Ltd. (MENS) a buy?
- MENS currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -1.83x).
- What is Jyong Biotech Ltd.'s quality score?
- MENS scores 24.13508178297004/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001954488, latest 20-F filed 2026-05-15) · EODHD · as of 7/1/2026, 7:23:23 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.